Companies SIGA Technologies Inc FollowJuly 27 (Reuters) - SIGA Technologies Inc (SIGA.O) on Thursday said it has won a new contract for its antiviral drug, Tpoxx, from the U.S. Department of Health and Human Services, sending the company's shares up about 20% after the bell. The order is for delivery of about $113 million worth of oral Tpoxx treatment courses and about $25 million worth of the intravenous formulation of the treatment, SIGA said. SIGA expects to fully deliver the order of oral Tpoxx drugs in 2023 and expects to start delivering IV TPOXX in 2024. Prior to the delivery of the IV drugs, it will focus on fulfilling a prior IV order, the company said. The U.S. Centers for Disease Control and Prevention expanded its use to help tackle the spread of mpox in 2022.

---

Persons: SIGA, Phil Gomez, Sriparna Roy, Devika Organizations: SIGA Technologies, U.S . Department of Health, Human Services, U.S . Food, Drug Administration, U.S . Centers for Disease Control, U.S . Department of Defense, World Health Organization, Thomson Locations: mpox, Bengaluru